Trials / Completed
CompletedNCT04987567
Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients
Effect of Antioxidant Docosahexaenoic Acid (DHA) Supplementation in Cystic Fibrosis Patients: A Randomized Placebo-controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Corporacion Parc Tauli · Academic / Other
- Sex
- All
- Age
- 6 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effect of antioxidant docosahexaenoic acid (DHA) in patients with cystic fibrosis. Half of participants will receive DHA, while the other half will receive placebo.
Detailed description
Several studies show that patients with cystic fibrosis (CF) usually have, compared to the normal population, low levels of linoleic acid (LA) and docosahexaenoic acid (DHA) and increase in arachidonic acid (AA), which is pro-inflammatory. Normalization or modification of this fatty acid pattern (AP) could reduce chronic inflammation. The aim of this study is to assess the effect of oral supplementation with DHA for one year in pediatric patients (6-18 years) with CF, on inflammatory parameters, AP profile, lung function (spirometry) and number of exacerbations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®) | Pearls of DHA (BrudyNen) |
| DIETARY_SUPPLEMENT | PLACEBO (OLIVE OIL) | Pearls manufactured to mimic DHA (BrudyNen). |
Timeline
- Start date
- 2018-03-21
- Primary completion
- 2020-02-20
- Completion
- 2020-02-20
- First posted
- 2021-08-03
- Last updated
- 2021-08-03
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT04987567. Inclusion in this directory is not an endorsement.